Oct 14, 2024 · Our data demonstrate that SAIL66, designed to engage CLDN6, CD3, and CD137, has the potential to enhance antitumor activity and provide a potent therapeutic option for …

SAIL66 is a novel tri-specific TCE, designed to bind to CLDN6 with one Fab arm and to both CD3 and CD137 with the other. In vitro characterization of SAIL66 demonstrates that it …

Mar 22, 2024 · SAIL66 induced activation of T cells, release of cytokines, and lysis of CLDN6-positive cancer cells. In vivo studies with a humanized mouse (huNOG) model showed that …

⇒ SAIL66 is a novel tri-specific TCE, designed to bind to CLDN6 with one Fab arm and to both CD3 and CD137 with the other. ⇒ In vitro characterization of SAIL66 demonstrates that it …

Oct 14, 2024 · To provide an efficacious treatment option for ovarian cancer, we generated SAIL66, a tri-specific antibody against CLDN6/CD3/CD137.

SAIL66 is a tri-specific monoclonal antibody designed to bind to CLDN6 on cancer cells with one Fab arm and to both CD3 and CD137 with the other Fab arm. This boosts immune activation …

Mar 22, 2024 · By boosting T cell activation through both CD3 and CD137 binding, SAIL66 shows potent anti tumor efficacy against CLDN6-positive cancers and are currently being evaluated …

SAIL66 is a tri-specific monoclonal antibody designed to bind to CLDN6 on cancer cells with one Fab arm and to both CD3 and CD137 with the other Fab arm. This boosts immune activation …

Oct 24, 2024 · SAIL66 is an anti-CLDN6/CD3/CD137 trispecific antibody and one of the next-generation T-cell engagers (TCEs) applying Chugai’s proprietary Dual-Ig ® technology. …

To provide an efficacious treatment option for ovarian cancer, we generated SAIL66, a tri-specific antibody against CLDN6/CD3/CD137.